BioXcel Therapeutics - Chapter 11 Case Summary

BioXcel Therapeutics filed for Chapter 11 following a slower-than-anticipated commercial launch of IGALMI® and mounting liquidity pressure under approximately $112 million of secured debt, and is pursuing a section 363 sale of substantially all assets ahead of a wind-down plan. An affiliate of Teva has executed a stalking horse asset purchase agreement providing $57.5 million in cash at closing plus up to $67.5 million in contingent milestone payments tied to the pending at-home sNDA and future commercial performance, subject to higher or otherwise better offers, with up to $19 million of new-money DIP financing from the existing lenders funding the process.

Business Description

BioXcel Therapeutics, Inc. ("BioXcel" or the "Company"), a New Haven, Connecticut-based biopharmaceutical company built on artificial intelligence to develop medicines in neuroscience, filed for Chapter 11 in the District of Delaware alongside its two Delaware limited liability company subsidiaries, OnkosXcel Therapeutics, LLC ("Onkos Therapeutics") and OnkosXcel Employee Holdings, LLC ("Onkos Employee Holdings" and, together with Onkos Therapeutics, "OnkosXcel"). BioXcel's model focuses on identifying new therapeutic indications for existing approved drugs and clinically evaluated product candidates, an approach designed to reduce the expense and time associated with drug development in diseases with substantial unmet medical needs. Onkos Therapeutics is focused on the development of medicines in immuno-oncology.

The Company's most advanced neuroscience clinical development program is BXCL501, a proprietary, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. BXCL501 is marketed as the FDA-approved product IGALMI®, a sublingual film placed under the tongue or behind the lower lip to treat acute agitation in adults with schizophrenia or bipolar I or II disorder, currently approved and commercially available only for use under the supervision of a health care provider. A pending supplemental new drug application ("sNDA") under the SERENITY program would permit at-home use for the acute treatment of agitation associated with bipolar disorders or schizophrenia; the FDA has assigned a target action date (a "PDUFA Date") of November 14, 2026. Through the TRANQUILITY program, BXCL501 has also been evaluated as a potential treatment for agitation associated with Alzheimer's dementia.

The Company has historically financed its operations primarily through public equity offerings and third-party debt financing and has not generated substantial product revenue to date. Net revenue from IGALMI® product sales was $0.6 million for the year ended December 31, 2025, against $2.3 million for the year ended December 31, 2024. For the six months ended June 30, 2026, the Debtors reported a net loss of $27.4 million, compared to a net loss of $26.4 million for the six months ended June 30, 2025. In its most recent financial statements, the Company identified conditions and events, including its history of significant losses, negative cash flows from operations, current debt obligations, and limited liquidity, that raise substantial doubt about its ability to continue as a going concern. Full-time headcount stood at 25 employees as of the Petition Date.

Corporate History

BioXcel was incorporated as a Delaware corporation on March 29, 2017, initially as a subsidiary of BioXcel LLC, formerly BioXcel Corporation ("BLLC"). BLLC contributed all of its rights to four proprietary investigational pharmaceutical formulations — BXCL501, BXCL701, BXCL502, and BXCL702 — together with related assets and liabilities, to BioXcel under an Asset Contribution Agreement dated June 30, 2017, as amended and restated November 7, 2017. Following the contribution, the parties contemplated potential collaborations through which BioXcel and BLLC technology would be used in conjunction to accelerate drug discovery and development; no development activity with BLLC has occurred since December 31, 2024. BLLC holds a contract with BioXcel to perform certain administrative and other services under a Separation and Shared Services Agreement dated June 30, 2017, as amended from time to time.

BioXcel completed the initial public offering of its common stock on March 12, 2018, and its shares have since traded on the Nasdaq Capital Market under the ticker symbol "BTAI." Within the current structure, Onkos Therapeutics and Onkos Employee Holdings are wholly owned subsidiaries of BioXcel: Onkos Therapeutics houses BioXcel's immuno-oncology assets and programs, including BXCL701, while Onkos Employee Holdings is a management holding company used to facilitate the grant of equity interests in OnkosXcel to service providers. Both subsidiaries are Debtors in these Chapter 11 Cases.

Operations Overview

IGALMI® and the Commercial Channel

IGALMI® (dexmedetomidine) sublingual film is BioXcel's only currently approved and marketed product. The FDA approved it in April 2022 for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults, for self-administration under the supervision of a health care provider. All of BioXcel's revenue relates to sales of IGALMI® for use in the healthcare setting. Substantially all IGALMI® sales are contracted and completed primarily through Cardinal Health, which warehouses all finished product on consignment and sells IGALMI® on demand to wholesalers throughout the country; those wholesalers in turn sell to end customers, generally hospitals, psychiatric institutions, and other healthcare facilities. Revenue is ultimately processed through Cardinal Health, net of any deductions for discounts, fees, and rebates.

The SERENITY Program and the Pending sNDA

In September 2024, BioXcel announced the launch of its SERENITY At-Home Phase 3 trial, designed to evaluate the safety and efficacy of BXCL501 in the at-home setting for the acute treatment of agitation associated with bipolar disorders or schizophrenia. Approval would expand IGALMI®'s use to the at-home setting, allowing patients experiencing agitation events to be treated at home without an overseeing healthcare professional. BioXcel announced in August 2025 that the trial met its primary objective, and on September 10, 2025 announced positive topline results demonstrating a favorable safety profile for BXCL501 administered at home without healthcare-provider supervision. That trial formed the basis of the sNDA filed with the FDA on January 14, 2026 and accepted in April 2026, carrying a PDUFA Date of November 14, 2026 — the FDA's goal date, rather than a statutory deadline, for deciding whether to approve the application.

The TRANQUILITY Program

Under its TRANQUILITY program, BioXcel is evaluating BXCL501 as a potential treatment for agitation associated with Alzheimer's dementia, a significantly larger patient population. The Company completed a Phase 3 trial by June 2023 and announced positive topline results, with a plan to develop a path to potential sNDA submission by the end of 2023. A second TRANQUILITY Phase 3 trial has been discussed with the FDA but has not been initiated, which the Declaration attributes to the Company's recent liquidity profile.

OnkosXcel and the Broader Pipeline

BXCL701, BioXcel's most advanced immuno-oncology asset and held through OnkosXcel, is an investigational oral innate immune activator designed to activate the body's existing immune cells to target and reduce cancerous tumors. It is being evaluated as a potential therapy for aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors, though further development has been deprioritized as part of BioXcel's broader cost-reduction efforts. A second neuropsychiatric candidate, BXCL502 (latrepirdine), had been planned for evaluation as a potential monotherapy, and possibly in combination with BXCL501, for the chronic treatment of agitation in patients with dementia and for acute stress disorder; formulation and further clinical development planning was paused as part of the strategic clinical reprioritization the Board approved in August 2023 (the "Clinical Reprioritization"). Additional pipeline concepts BXCL503 and BXCL504, explored as potential treatments for apathy and aggression, respectively, in patients with dementia, were likewise paused.

BioXcel also participates in investigator-sponsored trials evaluating BXCL501 in additional indications, led by clinical researchers at the Veterans Affairs Connecticut Healthcare System, Yale University Medical School, RTI International, Columbia University New York State Psychiatric Institute, and the University of North Carolina at Chapel Hill, and funded through cooperative agreements with the U.S. Department of Defense's Congressionally Directed Medical Research Program and the National Institute on Drug Abuse. BioXcel generally provides regulatory and operational support and investigational product while the sponsoring institutions lead the clinical and regulatory conduct of the trials, which are evaluating BXCL501 for opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder.

Intellectual Property, Manufacturing, and Footprint

BioXcel relies on a combination of patents, trademarks, trade secrets, know-how, and continuing innovation to protect the proprietary technologies, inventions, and improvements commercially important to its business, and also intends to rely on data exclusivity, market exclusivity, and patent term extensions where available. As of August 3, 2026, the neuroscience patent portfolio included 13 U.S. utility applications, 17 issued U.S. utility patents, 41 pending non-U.S. utility applications, 29 allowed or granted non-U.S. patents (including five in Japan), one pending U.S. design patent application, and two registered design patents in Japan. In the formulation family, BioXcel has granted or allowed patents in China, Europe, Eurasia, Japan, Mexico, and the U.S., and pending applications in the U.S., China, and other major markets.

The Company owns and operates no manufacturing facilities, relying instead on third-party manufacturing partners, in particular ARx, LLC, for the manufacture of its clinical supplies and commercial supply of IGALMI®, and expects to continue to rely on third parties for the manufacture of any future approved product candidates. The Debtors' sole facility is their New Haven, Connecticut corporate headquarters, approximately 18,285 square feet of office space, the lease for which was extended on a month-to-month basis effective March 1, 2026.

Workforce

Workforce reductions carried out under the Clinical Reprioritization approved by the Board in August 2023 cut headcount in two steps: approximately 15% in May 2024, and a further 15 employees, or approximately 28% of then-current headcount, in September 2024, completing the Clinical Reprioritization in October 2024. Full-time employees fell from approximately 60 at the time of the first Clinical Reprioritization announcement to 29 as of December 31, 2025, and to 25 as of the Petition Date.

Prepetition Obligations

As of the Petition Date, the Debtors carried approximately $112 million in funded debt, consisting entirely of principal outstanding under a senior secured Credit Agreement and Guaranty dated April 19, 2022, with Oaktree Fund Administration, LLC as administrative agent for the lenders. BioXcel is the borrower. At all times since closing, the lenders have consisted of funds affiliated with Oaktree Capital Management and the Qatar Investment Authority. The facility, a first-lien term loan, was made available for the U.S. commercial launch of BXCL501, clinical development of expanded indications for BXCL501, clinical development of BXCL701 and the Debtors' emerging oncology pipeline, and for working capital and general corporate purposes, including fees and expenses associated with the Credit Agreement and support of the research and development pipeline.

The RIFA and Its Conversion

Concurrently with execution of the Credit Agreement, BioXcel entered into a Revenue Interest Financing Agreement (the "RIFA") dated April 19, 2022 with purchasers likewise consisting of funds affiliated with Oaktree Capital Management and the Qatar Investment Authority, and with Oaktree as administrative agent. The RIFA provided for tranched payments to BioXcel to support development and commercialization of BXCL501 and other general corporate purposes, in exchange for royalty payments on net sales of BXCL501. BioXcel borrowed $70 million under the Credit Agreement and received $30 million under the RIFA during April 2022. In December 2023, ahead of the first scheduled minimum revenue covenant test date of December 31, 2023, the Company and lenders negotiated an amendment deferring that test date until December 31, 2024 and reducing the covenant's minimum revenue targets; in connection with that amendment, the RIFA was terminated and the purchasers' interest exchanged for $30 million in term loans under the Credit Agreement.

Deferrals and Bridge Financing

Under amendments entered into from June through August 2026, the lenders agreed to defer until August 31, 2026 the payment of principal and interest that would have been due on June 30, 2026, with the interest component paid in kind on June 30, 2026 by capitalizing it into principal. On August 24, 2026, the Debtors and lenders agreed to a further amendment providing for, among other things, $1.25 million in secured bridge financing to give the Debtors the liquidity necessary to complete preparation for these Chapter 11 Cases.

Trade Claims

Operating leanly while pursuing strategic alternatives, the Debtors minimized the incurrence of trade debt. They estimate that, in addition to their funded debt, they had approximately $17 million in unpaid trade and other ordinary course obligations as of the Petition Date, much of which represents amounts owed to existing or former professionals.

Events Leading to Bankruptcy

A Slow Commercial Launch

BioXcel was founded on the premise that artificial intelligence could accelerate drug development by identifying new therapeutic applications for existing approved drugs and clinically evaluated compounds. That vision produced a result in April 2022, when the FDA approved IGALMI® for the acute treatment of agitation associated with schizophrenia and bipolar I or II disorder in adults, a non-injection, non-sedation treatment for a condition affecting millions of patients and for which treatment options had been limited. Concurrent with approval, BioXcel entered into the Credit Agreement and the RIFA, securing aggregate financing commitments of up to $260 million to support the commercial launch, expanded clinical development of BXCL501, and general corporate purposes.

Following the July 2022 launch, BioXcel invested substantially in building a commercial organization and initiating clinical trials to expand the product's reach, but commercial adoption proved slower than anticipated. The Declaration attributes the shortfall to challenges typical of launching a novel product in a care-facility setting, including extended formulary review timelines, restrictive institutional purchasing protocols, and the need for sustained educational outreach to change established prescribing habits. Net revenue from IGALMI® sales fell from $2.3 million in 2024 to $0.6 million in 2025 as the Company scaled back its commercial organization in connection with the Clinical Reprioritization. Those revenue levels were not sufficient to cover operating expenses, debt service obligations, and ongoing clinical development costs.

The 2023 TRANQUILITY Trial and the Equity-Market Consequence

Between 2022 and 2023, BioXcel conducted its TRANQUILITY Phase 3 trial analyzing the efficacy of BXCL501 as a potential treatment for agitation associated with Alzheimer's dementia, engaging a contract research organization and other third parties to conduct the trial. On June 29, 2023, the Company publicly announced positive topline results and its intention to develop a path to a potential sNDA submission expanding IGALMI® to Alzheimer's dementia patients. The same announcement disclosed that the FDA had inspected one of the clinical trial sites and issued an FDA Form 483 notifying BioXcel of objectionable conditions at that site. Those conditions did not relate to the effectiveness of BXCL501 or its use with Alzheimer's patients, but to a falsified email sent to the FDA by the principal investigator overseeing the trial, who is not and was not a BioXcel employee. BioXcel then hired an independent third party to audit records from the trial, which found no additional evidence of fraud or data misconduct; the FDA ultimately concluded that voluntary action was indicated at the clinical site in connection with the Form 483.

BioXcel's share price dropped roughly 64% in a single day after the announcement and has not recovered. The Declaration attributes the Company's significantly impaired ability to raise additional equity financing, both to finalize the sNDA approval process for the SERENITY program and to restart the TRANQUILITY trial process, to that failure by the contract research organization and other third parties overseeing the trial and to the resulting drop in the stock price. BioXcel has several lawsuits pending against the contract research organization and other parties overseeing and responsible for the TRANQUILITY Phase 3 trial.

The Clinical Reprioritization

In August 2023, recognizing that its cash and financing resources were insufficient to simultaneously fund the breadth of its clinical pipeline, its commercial operations, and its debt service obligations, the Board approved a broad-based strategic clinical reprioritization. The Clinical Reprioritization concentrated resources on the highest-value near-term opportunities in the agitation market, principally the SERENITY program for at-home label expansion of IGALMI® and the associated sNDA, while pausing or deprioritizing programs requiring significant additional capital investment before generating near-term returns: the TRANQUILITY Phase 3 program, the BXCL502 program, the BXCL503 and BXCL504 pipeline concepts, and further development of the BXCL701 immuno-oncology program held through OnkosXcel. Targeted workforce reductions followed in May and September 2024, taking full-time headcount from approximately 60 to 29 by December 31, 2025.

Covenant Pressure and Successive Credit Agreement Amendments

Operating performance did not enable BioXcel to comply with the financial covenants or meet the payment obligations under the Credit Agreement, which in turn made it more difficult to raise alternative financing or pursue other strategic options. Of the up to $260 million in aggregate financing originally committed under the Credit Agreement and the companion RIFA, BioXcel drew $70 million under the initial tranche and $30 million under the RIFA, for $100 million in funded proceeds; the RIFA's $30 million was converted into term loans in December 2023. With capitalized payment-in-kind interest and amendment-related fees accruing on the outstanding balance, aggregate principal indebtedness under the Credit Agreement grew from the $101.25 million originally funded to approximately $112 million as of the Petition Date.

Governance Changes

On July 1, 2026, in connection with the Tenth Amendment, the Board formed the Strategic Process Committee and granted it exclusive authority to analyze, negotiate, and implement strategic alternatives, including any financing transaction, capital raise, potential sale of the Company or substantially all of its assets, or the potential filing of a Chapter 11 case. David Mack, appointed to the Board in November 2024, was the initial sole member. On August 12, 2026, Susan Atkins was appointed as a director and joined as the second member of the Strategic Process Committee; the same day, the Board formed the Claims Committee, with Atkins as sole member, and granted it authority to investigate potential claims and causes of action against any current and former officers and directors of the Debtors and any other third parties.

The Strategic Process and the Teva Bid

In parallel with the cost-reduction and liquidity-management efforts, BioXcel and its Board pursued a strategic review on two tracks: raising new equity capital to bridge to FDA approval of the at-home label expansion, and identifying a potential acquirer or strategic partner for BioXcel or its assets. The September 10, 2025 SERENITY At-Home safety results, which provided the foundational data for the January 2026 sNDA, were positioned as a catalyst for renewed interest from potential strategic partners and investors. In the fall of 2025, BioXcel engaged MTS Health Partners as investment banking advisor to evaluate strategic options, including a potential sale, a merger or other business combination, a collaboration, joint venture, or license agreement, or a significant private placement, and engaged Rodman & Renshaw LLC as placement agent to assist in raising equity capital through public and private offerings.

MTS and management conducted extensive outreach to pharmaceutical companies with existing neuroscience franchises and specialty pharmaceutical companies with established commercial platforms suited to the IGALMI® opportunity, and multiple parties conducted diligence on BioXcel's assets, clinical data, regulatory status, and commercial potential. Rodman assisted in completing a registered direct offering in March 2026 that generated net proceeds of approximately $6.9 million to bridge near-term liquidity needs. Despite meaningful engagement from prospective investors, partners, and purchasers, the magnitude of BioXcel's secured indebtedness relative to its enterprise value made it difficult to structure a transaction that would have a reasonable chance of stockholder approval, satisfy existing creditors, fund ongoing operations, and deliver meaningful value to equity holders on a consensual basis outside a court-supervised process.

Teva Pharmaceutical Industries Ltd. emerged from that process as the most viable strategic bidder, conducting extensive diligence on BioXcel's assets and regulatory portfolio, including the pending sNDA, and delivering a non-binding letter of intent proposing to acquire substantially all of BioXcel's assets through a section 363 sale process with Teva as stalking horse bidder. BioXcel continued to pursue new equity capital sufficient to bridge to FDA approval and avoid a Chapter 11 filing, but the Board and the Strategic Process Committee, with input from MTS and the Company's legal and restructuring advisors, determined that the section 363 sale to Teva presented a stronger value proposition and greater certainty to close than a standalone financing strategy, citing constrained liquidity, the magnitude of the debt obligations and the need for substantial concessions from the lenders that were not achievable, the uncertainty surrounding additional capital raises, and the near-term regulatory milestones a well-capitalized acquirer would be positioned to pursue. On August 26, 2026, the Board and the Strategic Process Committee determined that commencing Chapter 11 proceedings and conducting the contemplated marketing and sale process represented the best available means to maximize the value of BioXcel's assets.

Chapter 11 Filing

The Debtors filed voluntary petitions in the United States Bankruptcy Court for the District of Delaware, seeking joint administration for procedural purposes only, to pursue a value-maximizing sale of substantially all of their assets under section 363, followed by confirmation of a Chapter 11 plan to wind down the remaining estates and distribute sale proceeds to stakeholders in an orderly liquidation. Samir Saleem, a Managing Director of MERU, has served as Chief Restructuring Officer since August 26, 2026 and as financial advisor to the Debtors since September 19, 2024.

The Stalking Horse APA

BioXcel and an affiliate of Teva, as Stalking Horse Purchaser, negotiated and executed a stalking horse asset purchase agreement under which the purchaser has agreed to serve as stalking horse bidder for substantially all of the Debtors' assets. The Stalking Horse APA provides for $57.5 million in cash consideration at closing plus up to $67.5 million in contingent milestone payments tied to the outcome of the pending sNDA and future commercial performance, subject to higher or otherwise better offers through the postpetition bidding and, if necessary, auction process. The Debtors intend to continue marketing their assets actively during the cases, re-engaging with prospective buyers contacted during the prepetition strategic process and soliciting interest from additional parties.

Bidding Procedures

Through the Bid Procedures Motion, the Debtors seek approval of bidding procedures to govern the postpetition marketing and sale of substantially all of their assets; approval of their entry into the Stalking Horse APA and the bid protections provided thereunder, including a break-up fee and expense reimbursement payable solely upon certain negotiated termination events; approval of procedures for the assumption and assignment of executory contracts and unexpired leases in connection with any sale transaction; and scheduling of an auction, if necessary, a sale hearing, and related notice and objection deadlines. The proposed procedures set qualification requirements for potential bidders, minimum bid increments, bid deadline and deposit provisions, auction mechanics, procedures for selection of the successful bid and any backup bid, and assumption and assignment procedures. The motion is supported by the declaration of Daun Chung, a Partner at MTS.

The DIP Facility

The Debtors negotiated postpetition financing with their existing lenders, whose familiarity with the business, assets, and capital structure positioned them to move quickly. Those negotiations produced the $1.25 million in prepetition bridge financing under the existing Credit Agreement, funding operations in the period immediately preceding the filing, and a commitment to provide up to $19 million in new money debtor-in-possession financing, less amounts of OID.

Proceeds will fund the administration of the cases, maintain ongoing operations, support the postpetition sale process, and preserve value for the estates and creditors. The Debtors enter these cases with extremely limited liquidity and a constrained cash position, and state that without access to the DIP Facility they would be unable to fund administration of the cases, maintain operations, or pursue the sale contemplated by the Stalking Horse APA.

Other First-Day Relief

The Debtors also seek authority to continue their existing cash management system and honor certain prepetition obligations related thereto, with a waiver of certain operating guidelines and suspension of the time to comply with section 345(b); to pay certain prepetition employment and compensation obligations and maintain employee benefits programs; to maintain and administer existing customer programs and honor related prepetition obligations; to pay certain prepetition taxes and fees; to pay prepetition obligations incurred in the ordinary course in connection with the insurance program and continue the insurance premium financing program; and to establish utility procedures. Additional relief includes notice and objection procedures for transfers of equity securities together with a record date for notice and sell-down procedures for trading in claims against the estates, authority to redact certain personally identifiable information of individuals with modified equity-holder list requirements, joint administration, and retention of Stretto, Inc. as claims and noticing agent effective as of the Petition Date.